Kratom regulation and consumer safety in the United States

Kratom, a botanical product derived from the Mitragyna speciosa tree native to Southeast Asia, remains in a complex regulatory position in the United States. While the product is federally unscheduled, the FDA has stated that no kratom-containing products are legally marketed as prescription drugs, over-the-counter drugs, or dietary supplements.

Because kratom lacks standard FDA dietary supplement oversight, consumers face an inconsistent regulatory landscape. In New York, sales are permitted at the state level, though local jurisdictions may impose additional restrictions. This regulatory gap means that standardized testing requirements and mandatory labeling accuracy do not automatically apply, leaving much of the safety burden to industry self-regulation.

Programs such as the American Kratom Association’s Good Manufacturing Practices Qualified Vendor program offer voluntary third-party audits for manufacturing and batch testing. However, since participation is not mandatory for all companies, consumers are encouraged to seek out independent laboratory reports, complete ingredient information, and clear batch identification to verify product quality and alkaloid content.